Héma-Québec Seroprevalence Study

The objectives of the study are to : 1. Estimate the proportion of population that was infected by the SARS-CoV-2 virus in the province of Quebec, particularly in the greater Montreal area, during the first wave of COVID-19; 2. Monitor the evolution of this proportion until the end of the pandemic and; 3. Estimate the proportion of people infected with SARS-CoV-2 who remained asymptomatic during the first wave of the disease.

Overview

Acronym
HQ
Investigators
Dr. Marc Germain
Héma-Quebec
Contacts
Dr. Marc Germain
Héma-Quebec

General Design

Study design
Cohort
Start - End Year
2020 -
General Information on Follow Up (profile, frequency)
In order to continue monitoring the evolution of COVID-19 in Quebec, the study may be repeated at regular intervals until the end of the pandemic. The first follow-up will begin in January 2021 and will continue over a 7-week period in the context of the second wave of the pandemic.
Recruitment Target
  • Individuals
Number of Participants
7,691
Number of Participants with Biological Samples
7,691

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Population

HQ population
The population is composed of individuals aged 18 to 81 who donated blood between May 25 and July 9 2020 in 14 of Quebec's 18 health regions.

Selection Criteria

Minimum age
18
Maximum age
81
Countries
  • Canada
Canadian Provinces
  • Quebec
Health Status
  • Being eligible for regular blood donation (good health)
Other Criteria
Exclusion: symptoms of COVID-19 in the last 14 days prior to their donation

Sources of Recruitment

Specific Population
  • Other specific population : Blood donors
Supplementary Information
The participants of this seroprevalence study were regular blood donors who completed their donation between May 25 and July 9 2020.

Sample Size

Number of Participants
7,691
Number of Participants with Biological Samples
7,691

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 HQ - Wave 1
  • Biosamples
  • Blood
2020 (May) 2020 (July)
1 HQ - Nested case-control study
  • Questionnaires
2020 (May) 2020 (July)
2 HQ - Wave 2
  • Biosamples
  • Blood
2021 (January) 2021 (March)

Participating Studies

Acronym Name Study design Countries

Harmonization Initiatives Included

Acronym Name

Datasets

Name Data Collection Events Variables

Areas of Information Collected

Socio-demographic and economic characteristics
Death
Lifestyle and behaviours
Physical measures and assessments
Birth, pregnancy and reproductive health history
Laboratory measures
Perception of health, quality of life, development and functional limitations
Cognition, personality and psychological measures and assessments
Diseases
Life events, life plans, beliefs and values
Symptoms and signs
Preschool, school and work life
Medication and supplements
Social environment and relationships
Non-pharmacological interventions
Physical environment
Health and community care services utilization
Administrative information

Variables Content Summary

Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected

Networks

Acronym Name Harmonization Initiatives Individual Studies
Last Update: 2024-02-27T14:21:59.213